A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects

• Những tác giả chính: Azra Hussaini (Tác giả), Rajat Mukherjee (Tác giả), Dina M. Berdieva (Tác giả), Christen Glogowski (Tác giả), Richard Mountfield (Tác giả), Peter T.C. Ho (Tác giả)
• Định dạng: Sách
• Được phát hành: Wiley, 2020-03-01T00:00:00Z.
• Những chủ đề: article
• Truy cập trực tuyến: Connect to this object online.

The purpose of this study was to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of BOS161721, a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody that inhibits interleukin‐21 (IL‐21) bioactivity. This randomized, single‐cente...